CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort
- 295 Downloads
To determine if molecular and immunohistochemical (IHC) features of the HRPT2/CDC73 gene and its product, parafibromin, predict the natural history of parathyroid malignancy, particularly atypical adenoma, as seen in a single-centre patient cohort.
Matched tumor and non-tumor tissues were obtained from 46 patients with parathyroid carcinoma (CA) (n = 15), atypical adenoma (AA) (n = 14) and typical adenoma (TA) (n = 17), as defined by standardized histopathological criteria. Exons and exon-intron boundaries of the CDC73 gene were sequenced to identify germline or somatic mutations. IHC staining for parafibromin was performed and scored as positive if nuclear staining was at least partially IHC-positive.
Mutations of CDC73 were observed in 9/15 (60 %) CA, 2/14 (14 %) AA, and 1/17 (6 %) TA tumors. A recurrent two basepair mutation in exon 7 -- c.679_680delAG -- accounted for half of all identified mutations. Absence of parafibromin nuclear staining was noted in 8/12 (67 %) CA, 2/13 (15 %) AA, and 3/17 (18 %) TA tumors. Median follow up times were 88 months for CA, 76 months for AA, and 104 months for TA patients. One patient, a member of a previously reported multiplex family with a germline CDC73 mutation was found to have a second adenoma after removal of an atypical adenoma.
Molecular screening and IHC are both useful tools in the differential diagnosis of parathyroid tumors, but both have limited sensitivity and specificity. CDC73 mutations and negative immunostaining were common in atypical adenomas, but no local recurrence was observed in any case with successful surgical removal after follow-up periods of 27 to 210 months.
KeywordsCDC73 HRPT2 Parafibromin Parathyroid tumours Atypical adenoma
- 6.L. Bondeson, L. Grimelius, R.A. DeLellis, R. Lloyd, G. Akerstrom, C. Larsson, A. Arnold, C. Eng, E. Shane, J.P. Bilezikian, Parathyroid carcinoma, in Pathology and genetics of tumours of endocrine organs. WHO classification of tumours, ed. by R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (IARC Press, Lyon, 2004), pp. 124–127Google Scholar
- 8.J.D. Carpten, C.M. Robbins, A. Villablanca, L. Forsberg, S. Presciuttini, J. Bailey-Wilson, W.F. Simonds, E.M. Gillanders, A.M. Kennedy, J.D. Chen, S.K. Agarwal, R. Sood, M.P. Jones, T.Y. Moses, C. Haven, D. Petillo, P.D. Leotlela, B. Harding, D. Cameron, A.A. Pannett, A. Höög, H. Heath 3rd, L.A. James-Newton, B. Robinson, R.J. Zarbo, B.M. Cavaco, W. Wassif, N.D. Perrier, I.B. Rosen, U. Kristoffersson, P.D. Turnpenny, L.O. Farnebo, G.M. Besser, C.E. Jackson, H. Morreau, J.M. Trent, R.V. Thakker, S.J. Marx, B.T. Teh, C. Larsson, M.R. Hobbs, HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676–680 (2002)PubMedCrossRefGoogle Scholar
- 10.T.M. Shattuck, S. Valimäki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, M.E. Wierman, K. Tojo, C.M. Robbins, J.D. Carpten, L.O. Farnebo, C. Larsson, A. Arnold, Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722–1729 (2003)PubMedCrossRefGoogle Scholar
- 11.C.C. Juhlin, A. Villablanca, K. Sandelin, F. Haglund, J. Nordenstrom, L. Forsberg, L. Branstrom, T. Obara, A. Arnold, C. Larsson, A. Höög, Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr. Relat. Cancer 14, 501–512 (2007)PubMedCrossRefGoogle Scholar
- 12.F. Cetani, E. Ambrogini, P. Viacava, E. Pardi, G. Fanelli, A.G. Naccarato, S. Borsari, M. Lemmi, P. Berti, P. Miccoli, A. Pinchera, C. Marcocci, Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur. J. Endocrinol. 156, 547–554 (2007)PubMedCrossRefGoogle Scholar
- 13.V.M. Howell, C.J. Haven, K. Kahnoski, S.K. Khoo, D. Petillo, J. Chen, G.J. Fleuren, B.G. Robinson, L.W. Delbridge, J. Philips, A.E. Nelson, U. Krause, K. Hammje, H. Dralle, C. Hoang-Vu, O. Gimm, D.J. Marsh, H. Morreau, B.T. Teh, HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. 40, 657–663 (2003)PubMedCrossRefGoogle Scholar
- 14.V.M. Howell, A. Gill, A. Clarkson, A.E. Nelson, R. Dunne, L.W. Delbridge, B.G. Robinson, B.T. Teh, O. Gimm, D.J. Marsh, Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J. Clin. Endocrinol. Metab. 94, 434–441 (2009)PubMedCrossRefGoogle Scholar
- 16.F. Cetani, E. Pardi, S. Borsari, P. Viacava, G. Dipollina, L. Cianferotti, E. Ambrogini, E. Gazzerro, G. Colussi, P. Berti, P. Miccoli, A. Pinchera, C. Marcocci, Genetic analysis of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 89, 5583–5591 (2004)PubMedCrossRefGoogle Scholar
- 17.M.H. Tan, C. Morrison, P. Wang, X. Yang, C.J. Haven, C. Zhang, P. Zhao, M.S. Tretiakova, E. Korpi-Hyovalti, J.R. Burgess, K.C. Soo, W.K. Cheah, B. Cao, J. Resau, H. Morreau, B.T. Teh, Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin. Cancer Res. 10, 6629–6637 (2004)PubMedCrossRefGoogle Scholar
- 18.A.J. Gill, A. Clarkson, O. Gimm, J. Keil, H. Dralle, V.M. Howell, D.J. Marsh, Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am. J. Surg. Pathol. 30, 1140–1149 (2006)PubMedCrossRefGoogle Scholar
- 20.S. Mangray, K.C. Kurek, E. Sabo, R.A. DeLellis, Immunohistochemical expression of parafibromin is of limited value in distinguishing parathyroid carcinoma from adenoma. Mod. Pathol. 21, 108A (2008). abstractGoogle Scholar
- 24.V. Guarnieri, L. Canaff, F.H.J. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y.L. Wong, A. Notarangelo, L. D’Agruma, M. Sacco, D.E.C. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95, 1819–1829 (2010)PubMedCrossRefGoogle Scholar
- 25.V. Guarnieri, A. Scillitani, L.A. Muscarella, C. Battista, N. Bonfitto, M. Bisceglia, S. Minisola, M.L. Mascia, L. D’Agruma, D.E.C. Cole, Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J. Clin. Endocrinol. Metab. 91, 2827–2832 (2006)PubMedCrossRefGoogle Scholar
- 26.V. Guarnieri, M. Bisceglia, N. Bonfitto, F. Cetani, C. Marcocci, S. Minisola, C. Battista, I. Chiodini, D.E.C. Cole, A. Scillitani, Re: Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 144, 839–840 (2008)PubMedCrossRefGoogle Scholar
- 27.L. Grimelius, R.A. DeLellis, L. Bondeson, G. Akerstrom, A. Arnold, K.O. Frinssila, G.N. Hendy, D. Dupuy, C. Eng, Parathyroid adenoma, in Pathology and genetics of tumours of endocrine organs. WHO classification of tumours, ed. by R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (IARC Press, Lyon, 2004), pp. 128–132Google Scholar
- 34.T.G. Kelly, T.M. Shattuck, M. Reyes-Mugica, A.F. Stewart, W.F. Simonds, R. Udelsman, A. Arnold, T.O. Carpenter, Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J. Bone Miner. Res. 21, 1666–1671 (2006)PubMedCrossRefGoogle Scholar